Last updated June 30, 2025
Introduction
For decades, adenosine has been the first-line pharmacologic agent for the management of hemodynamically stable supraventricular tachycardia (SVT) in emergency settings. Its rapid onset of action, ultra-short half-life, and transient atrioventricular (AV) nodal blockade offer both therapeutic and diagnostic utility. However, due to its uncomfortable side effect profile, there has been growing interest in calcium channel blockers (CCBs) as alternative agents, with the aim of improving patient tolerability. This raises an important clinical question: do CCBs offer comparable efficacy to adenosine in the acute management of stable SVT?
Pharmacology
Drug | Mechanism | Onset | Half-Life |
Adenosine | Inhibits AV node via A1 receptor (K⁺↑, Ca²⁺↓) | ~30 sec | <10 sec |
CCBs (verapamil/diltiazem) | AV nodal L-type Ca²⁺ channel blockade | ~1–3 min | ~30–60 min |
Current guidelines
According to the 2020 AHA and 2015 ACC/AHA/HRS guidelines, adenosine remains the first-line pharmacologic agent for the treatment of regular, narrow-complex SVT, supported by a Class I recommendation. Calcium channel blockers such as verapamil or diltiazem are considered a reasonable alternative when adenosine is either contraindicated or ineffective (Class IIa recommendation). However, CCBs should be avoided in patients with hypotension, heart failure with reduced ejection fraction (HFrEF), or preexcited atrial fibrillation (e.g., WPW) due to potential harm. Notably, the guidelines do not endorse the superiority of one agent over the other.
2017 Cochrane Review (Alabed et al)
The Paper
Methods
Key Results
Author Conclusions
RAMMBO Appraisal
BEEM Appraisal Checklist
2025 Feng & Liu Meta-analysis
The Paper
Methods
Key Results
Author conclusions
RAMMBO Appraisal
BEEM Appraisal Checklist
Summary
Feature | Adenosine | CCBs (Verapamil/Diltiazem) |
Efficacy | ~90–91% | ~93% (no significant difference) |
Onset | ~30 seconds | ~1–3 minutes |
Half-Life | <10 seconds | 30–60 minutes |
Time to Conversion | Faster | Slower (~7 minutes longer) |
Side Effects | Chest tightness, flushing, dyspnea | Mild hypotension, bradycardia |
AHA Recommendation | First-line (Class I) | Reasonable alternative (Class IIa) |
The Bottom Line
Both the 2017 Cochrane Review and the 2025 Feng & Liu meta-analysis found no significant difference in efficacy between adenosine and calcium channel blockers (CCBs) for converting stable SVT to sinus rhythm. While CCBs may be associated with a slightly higher risk of hypotension (not statistically significant), adenosine produces more frequent—but transient—patient discomfort (e.g., flushing, chest tightness, dyspnea). Importantly, none of the available studies systematically evaluated patient experience or tolerability, highlighting a major gap in the literature. In the absence of strong evidence favoring one agent, treatment choice should be guided by patient-specific factors, comorbidities, and clinical context.
Sources
- Alabed S, Sabouni A, Providencia R, et al. Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia. Cochrane Database Syst Rev. 2017;10(10):CD005154. doi:10.1002/14651858.CD005154.pub4
- Feng X, Liu J. Efficacy and safety of adenosine for supraventricular tachycardia: a meta-analysis utilizing BioMedGPT-LM-7B. BMC Cardiovasc Disord. 2025;25(1):158. doi:10.1186/s12872-025-04595-x
- Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2016;67(13):e27–e115. doi:10.1016/j.jacc.2015.08.856
- Panchal AR, Bartos JA, Cabañas JG, et al. Part 3: Adult basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2020;142(16_suppl_2):S366–S468. doi:10.1161/CIR.0000000000000916
This post is for education only and not medical advice.